Navigation Links
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Date:7/22/2011

TOKYO, July 22, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama. (Abstract no. 10428)

The trial was a randomized, double-blind, placebo-controlled study with a primary outcome measure of overall survival involving 172 patients with refractory metastatic colorectal cancer who had received standard chemotherapy at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin. The results indicated that the TAS-102 significantly improved overall survival compared with the placebo (overall survival median: 9.0 months vs. 6.6 months) and significantly reduced the risk of mortality (HR=0.56, p=0.0011). Also, no instances of treatment-related mortality were reported. The most frequently reported adverse drug reaction with a CTCAE grade 3 or higher was neutropenia. Grade 3 or higher diarrhea, fatigue, nausea, and other adverse reactions were no more than 10%.

In light of these results, Taiho Pharmaceutical will proceed with global development of TAS-102 so that this drug can be offered as soon as possible to metastatic colorectal cancer patients who have exhausted proven treatment options and there remains a high unmet medical need.

About TAS-102:

TAS-102 is a novel oral nucleoside antitumor agent with a novel mechanism of action, composed of a mixture of Trifluorothymidine (FTD), which demonstrates antitumor effects through incorporation into DNA, and 5-chloro-6-(2-iminopyrrolidin-1-yl)-methyl-2,4(1H,3H)-pyrimidinedione hydrochloride (TPI), which inhibits the degradation of FTD. Phase I trials began in Japan in 2005, and the drug continues to be developed as a treatment for colorectal cancer refra
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , August 27, 2015 ... Persistence Market Research titled "Global Market Study on ... Growth by 2021", the urinary catheters market is expected to ... of 2015. It is anticipated to expand at ... reach US$1,755.0 Mn by 2021. View ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... and Chief Executive Officer, will present at the Cowen ... Boston Marriott Copley Place.  The presentation is scheduled for ...
... 2011 HeartWare International, Inc. (Nasdaq: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... a.m. Eastern Time on Tuesday, March 15, 2011. The ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:8/27/2015)... ... 27, 2015 , ... StayWell, a leading provider of patient ... ICD-10 ready and available to all clients. All Krames Patient Education content has ... more targeted and return a more comprehensive data set of content than the ...
(Date:8/27/2015)... , ... August 27, 2015 , ... In addition to ... University now offers a third doctoral program at its main campus in Reading: Doctor ... terminal degree program designed to prepare advanced practice nurses for the highest level of ...
(Date:8/27/2015)... ... August 27, 2015 , ... Market ... market research promotion on the Internet. MarketPublishers.com is now authorised to distribute ... the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: "Black ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
(Date:8/27/2015)... La Mirada, Ca (PRWEB) , ... August 27, ... ... throughout Southern California including Los Angeles, Riverside, San Bernardino, and Orange ... executive employees, Healthpointe’s executive physical exams are offered annually at all of its ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Healthpointe Now Offering Executive Physicals 2
... Using small molecules (purine analogs) scientists ... lung cancer, a common obstacle to successful, ... - HTDS www.htdsmedical.com (HTDS) - The issuer,s ... brings attention to its Mindup Bioresearch cancer project working ...
... At a Los Angeles gala, family and friends ... in paying tribute to women,s health advocate and fitness ... Beverly Wilshire Hotel where friends toasted LaLanne for being ... in shape and lead healthier lifestyles. , (Photo: ...
... French . , Winnipeg (October 14, 2009) The ... (CIHR) today announced support for five new research projects ... virus. "Canada is a global leader in ... on a safe and effective H1N1 vaccine," said Health Minister ...
... tumor growth without harmful therapies, study suggests , WEDNESDAY, ... scientists closer to their goal of treating pancreatic cancer ... The researchers, who were scheduled to report their findings ... 11-15 in Chicago, have created a bioengineered "construct" that ...
... GLENDALE, Calif., Oct. 14 Although some parents may ... www.LakesideCommunityHealthcare.com , one of Southern California,s ... about both the safety of and access to the ... www.LakesideFluInfo.com to give patients direct access ...
... Oct. 14 Cardium Therapeutics (NYSE Amex: CXM ... 2b clinical trial of Excellarate(TM) for the potential treatment ... on the Company,s Gene Activated Matrix (GAM) technology platform. ... product candidate (GAM501, which is a combination of Ad5PDGF-B ...
Cached Medicine News:Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 2Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 3Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 4Health News:Jack LaLanne Celebrated as Fitness Icon at Star-Studded Birthday Bash 2Health News:Government of Canada supports scientific research to deepen knowledge of H1N1 flu virus 2Health News:Stem Cells Being Tested to Fight Pancreatic Cancer 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14
Cold light source single outlet....
Cold light source single outlet....
Cold light source single outlet....
Cold light source triple outlet....
Medicine Products: